Iwaki, Sho
Kadowaki, Shigenori http://orcid.org/0000-0001-9923-5309
Honda, Kazunori
Narita, Yukiya
Masuishi, Toshiki
Taniguchi, Hiroya
Ando, Masashi
Muro, Kei
Sawabe, Michi
Suzuki, Hidenori
Nishikawa, Daisuke
Beppu, Shintaro
Terada, Hoshino
Kishikawa, Toshihiro
Kawakita, Daisuke
Hanai, Nobuhiro
Article History
Received: 16 November 2023
Accepted: 6 March 2024
First Online: 30 March 2024
Declarations
:
: K. Honda reports research funding from Pfizer. S. Kadowaki reports honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Bayer, Merck Biopharma, Taiho Pharmaceutical, Eisai, Daiichi Sankyo, MSD, Chugai, and Otsuka Pharmaceutical and research funding from Bristol-Myers Squibb, Ono Pharmaceutical, Bayer, Daiichi Sankyo, MSD, Chugai, Janssen, Nobelpharma, and Eli Lilly. Y. Narita reports honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Yakult Honsha, Taiho Pharmaceutical, Eli Lilly, Daiichi Sankyo, and AstraZeneca and research funding from Ono Pharmaceutical, Bristol-Myers Squibb, and AstraZeneca. T. Masuishi reports honoraria from Takeda Pharmaceutical, Chugai, Merck Biopharma, Taiho Pharmaceutical, Bayer, Eli Lilly, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono Pharmaceutical, Bristol-Myers Squibb, and Nippon Kayaku and research funding from MSD, Daiichi Sankyo, Ono Pharmaceutical, Novartis, Amgen, Syneos Health Clinical, Boehringer Ingelheim, Pfizer, Cimic Shift Zero, and Eli Lilly. H. Taniguchi reports honoraria from Takeda Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Merck Biopharma and research funding from Takeda Pharmaceutical and Daiichi Sankyo. M. Ando reports honoraria from Eisai, Ono Pharmaceutical, Chugai, and Taiho Pharmaceutical. K. Muro reports honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Daiichi Sankyo, MSD, and Taiho Pharmaceutical and research funding from Amgen, Astellas, PRA Health Sciences, Taiho Pharmaceutical, Chugai, PAREXEL International, Ono Pharmaceutical, Sanofi, MSD and Novartis. N. Hanai reports honoraria from MSD, Merck Biopharma, Eisai, Bristol-Myers Squibb, Rakuten Medical, and Ono Pharmaceutical and research funding from GlaxoSmithKline, Chugai, Rakuten Medical, MSD, and Adlai Nortye. No disclosures were reported by the other authors.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Boards of the Aichi Cancer Center Hospital (IR051031).